The Immunology of Hormone Receptor Positive Breast Cancer.
The Immunology of Hormone Receptor Positive Breast Cancer.
复制标题
激素受体阳性乳腺癌的免疫学
DOI：
10.3389/fimmu.2021.674192
复制
发表时间：
2021
影响因子：
7.3
通讯作者：
Guerriero JL
中科院分区：
文献类型：
--
作者：
Goldberg J;Pastorello RG;Vallius T;Davis J;Cui YX;Agudo J;Waks AG;Keenan T;McAllister SS;Tolaney SM;Mittendorf EA;Guerriero JL
免疫检查点阻断(ICB)使癌症患者的治疗发生了革命性的变化。ICB的主要焦点一直是重振适应性免疫反应，即激活细胞毒性T细胞。ICB对晚期乳腺癌的疗效不大，因为乳腺肿瘤通常建立免疫抑制肿瘤微环境(TME)。三阴性乳腺癌(TNBC)与肿瘤浸润性淋巴细胞(TIL)的浸润有关，临床上对ICB有反应。相反，激素受体阳性(HR+)乳腺癌的特点是低TIL浸润率和对ICB的最低反应。在这里，我们回顾了HR+乳腺肿瘤如何建立一个没有TIL的TME，具有低的HLAI类表达，以及如何招募T细胞以外的免疫细胞，这些都影响了治疗反应。此外，我们回顾了用于表征TME成分的新技术，揭示了肿瘤相关巨噬细胞(TAM)在HR+癌症中含量丰富，具有高度的免疫抑制作用，与肿瘤进展、化疗和ICB耐药、转移和低生存率有关。我们揭示了新的治疗靶点和与ICB联合增强抗肿瘤免疫反应的可能性，这可能在HR+乳腺癌中具有巨大的潜力。
Immune checkpoint blockade (ICB) has revolutionized the treatment of cancer patients. The main focus of ICB has been on reinvigorating the adaptive immune response, namely, activating cytotoxic T cells. ICB has demonstrated only modest benefit against advanced breast cancer, as breast tumors typically establish an immune suppressive tumor microenvironment (TME). Triple-negative breast cancer (TNBC) is associated with infiltration of tumor infiltrating lymphocytes (TILs) and patients with TNBC have shown clinical responses to ICB. In contrast, hormone receptor positive (HR+) breast cancer is characterized by low TIL infiltration and minimal response to ICB. Here we review how HR+ breast tumors establish a TME devoid of TILs, have low HLA class I expression, and recruit immune cells, other than T cells, which impact response to therapy. In addition, we review emerging technologies that have been employed to characterize components of the TME to reveal that tumor associated macrophages (TAMs) are abundant in HR+ cancer, are highly immune-suppressive, associated with tumor progression, chemotherapy and ICB-resistance, metastasis and poor survival. We reveal novel therapeutic targets and possible combinations with ICB to enhance anti-tumor immune responses, which may have great potential in HR+ breast cancer.
登录
查看更多内容
DOI：
10.1093/annonc/mdx266
发表时间：
2017-08-01
期刊：
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子：
--
作者：
Ali HR;Dariush A;Thomas J;Provenzano E;Dunn J;Hiller L;Vallier AL;Abraham J;Piper T;Bartlett JMS;Cameron DA;Hayward L;Brenton JD;Pharoah PDP;Irwin MJ;Walton NA;Earl HM;Caldas C
通讯作者：
Caldas C
影响因子：
22.7
作者：
Ali, H. Raza;Jackson, Hartland W.;Bodenmiller, Bernd
通讯作者：
Bodenmiller, Bernd
影响因子：
50.5
作者：
Ali, H. R.;Glont, S. -E.;Caldas, C.
通讯作者：
Caldas, C.
影响因子：
64.8
作者：
Cabrita, Rita;Lauss, Martin;Jonsson, Goran
通讯作者：
Jonsson, Goran
影响因子：
10.3
作者：
Bareche, Yacine;Buisseret, Laurence;Sotiriou, Christos
通讯作者：
Sotiriou, Christos